- Home
- REFI vs EDIT Comparison
REFI vs EDIT Comparison
Compare REFI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | EDIT |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 233.3M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | REFI | EDIT |
|---|---|---|
| Price | $13.16 | $2.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $20.00 | $4.13 |
| AVG Volume (30 Days) | 108.6K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 15.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | $46,383,000.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $0.91 |
| 52 Week High | $16.29 | $4.54 |
Technical Indicators
Market Signals| Indicator | REFI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 42.04 |
| Support Level | $12.66 | $2.40 |
| Resistance Level | $13.49 | $2.61 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 69.08 | 46.61 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.